Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Completed
CT.gov ID
NCT02715856
Collaborator
National Cancer Institute (NCI) (NIH)
72
1
2
65.5
1.1

Study Details

Study Description

Brief Summary

This randomized pilot trial studies telemonitoring after surgery to preserve limb function in optimizing mobility in cancer survivors with cancer spread to the bone. The use of mobile devices for telemonitoring may improve the delivery of cost-effective, high-quality, standardized surveillance of cancer survivors.

Condition or Disease Intervention/Treatment Phase
  • Other: Monitoring Device
  • Other: Physical Activity Measurement
  • Other: Quality-of-Life Assessment
  • Other: Questionnaire Administration
  • Procedure: Standard Follow-Up Care
  • Other: Survey Administration
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. To develop and evaluate the feasibility of a method that enhances surveillance in cancer survivors by using mobile devices in addition to face-to-face visits following surgery for bone metastases.
SECONDARY OBJECTIVES:
  1. To evaluate how well the face-to-face follow-up format can be adapted to using mobile devices for remote surveillance.

  2. Limited efficacy testing of the remote surveillance program. III. To obtain information on acceptability of the mobile surveillance format by patients and clinicians.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (CONTROL): Patients undergo standard face-to-face follow up visits at 2, 6, 12, and 24 weeks after surgery. Patients also undergo a physical activity assessment over 15 minutes.

GROUP II (MOBILE SURVEILLANCE): Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.

After completion of study, patients are followed up at 24-25 weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
72 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Using Telemonitoring to Optimize the Mobility of Cancer Survivors With Skeletal Metastases After Surgery to Preserve Limb Function
Actual Study Start Date :
Apr 13, 2016
Actual Primary Completion Date :
Sep 28, 2021
Actual Study Completion Date :
Sep 28, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Group I (standard follow up, physical activity measurement)

Patients undergo standard face-to-face follow up visits at 2, 6, 12, and 24 weeks after surgery. Patients also undergo a physical activity assessment over 15 minutes.

Other: Physical Activity Measurement
Undergo physical activity measurement
Other Names:
  • Activity
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other Names:
  • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies

    Procedure: Standard Follow-Up Care
    Undergo standard follow-up care

    Other: Survey Administration
    Ancillary studies

    Experimental: Group II (mobile surveillance)

    Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.

    Other: Monitoring Device
    Undergo surgical wound and physical activity monitoring
    Other Names:
  • Monitor
  • Other: Physical Activity Measurement
    Undergo physical activity measurement
    Other Names:
  • Activity
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other Names:
  • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies

    Procedure: Standard Follow-Up Care
    Undergo standard follow-up care

    Other: Survey Administration
    Ancillary studies

    Outcome Measures

    Primary Outcome Measures

    1. Inter-Rater Agreement on the Physician Assessed Score [7 months]

      Inter-rater agreement on the physician assessed score defined as less than 10% difference between the Musculoskeletal Tumor Society (MSTS) scores evaluated using video vs. face-to-face follow ups.

    Secondary Outcome Measures

    1. Completion of Follow-Up Assessments [Up to 25 weeks]

      Participant considered having completed the follow-up assessments if the three outcomes are documented for the 2-, 6-, 12, and 24-week evaluations. Follow-up assessment information taken from Musculoskeletal Tumor Society Scores (MSTS), Timed "Up and Go" test (TUG), and Patient Reported Outcomes Measurement Information System (PROMIS).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Have been scheduled for an intramedullary nailing (IM) surgery with the department of Orthopaedic Oncology at University of Texas (UT) MD Anderson Cancer Center

    • Are able to read and write English 3) Are 18 years or older

    • Are willing and able to use a smartphone or tablet comfortably

    • Have access to mobile hot spot, wireless internet, and/or cellular service

    • Must have a caregiver or assistance at home who can assist with collecting physical therapy (PT) measures

    Exclusion:

    N/A

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 M D Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • M.D. Anderson Cancer Center
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Robert L Satcher, M.D. Anderson Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    M.D. Anderson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT02715856
    Other Study ID Numbers:
    • 2015-0966
    • NCI-2016-00544
    • 2015-0966
    • 2015-00051255-Y1
    First Posted:
    Mar 22, 2016
    Last Update Posted:
    Oct 12, 2021
    Last Verified:
    Oct 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by M.D. Anderson Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 12, 2021